… by which the neuroendocrine macro-environment affected cervical tumor growth, invasion
and therapy resistance, while showing that miR-145 served as a target for CC therapy (36). …

… risk of cervical cancer development [78]. Furthermore, variants of major histocompatibility
complex (MHC) alleles are associated with increased risk of persistent HPV infection and …

… treatment of cervical cancer. Although this cancer poses a far greater health concern in less
developed … The primary cause in development of cervical cancer is human papillomavirus (…

… to carcinogenesis and tumor progression predominantly … development of cervical neoplasia.
It is now accepted that HPV may be necessary but not sufficient to cause of cervical cancer …

… , perturbation of antitumor immune response, alteration of gene … targets for the treatment of
cervical cancer associated with HPV … therapy strategies against cervical cancer development. …

… This is of clear importance in the context of cervical cancer, and studies with recently
developed ATR inhibitors, combined with platin-based chemoradiotherapy are eagerly awaited. …

… Therapeutic modulation of the DDR is an attractive strategy to increase treatment response
… knowledge surrounding the development of such therapies for cervical cancer in the context …

… HPV DNA is the only molecular marker developed for the diagnosis of cervical cancer.
Molecular abnormalities such as chromosomal anomalies, DNA mutations, cell cycle check points…

… Cervical cancer is the fourth most common cancer among … aetiology for the development of
cervical cancer. Infection by high… cervical epithelial cells are key early events in the neoplastic …

… E6 and E7 proteins inactivate and degrade tumor suppressors p53 and … progression. HPV
E6 and E7 antigens are ideal targets for the development of therapies for cervical cancer and …